Ankylosing Spondylitis
Conditions
Keywords
Ankylosing spondylitis, Physical training program
Brief summary
Purpose: to assess the efficacy of a physical training program in patients with ankylosing spondylitis (AS) in a randomized controlled study
Detailed description
AS is a chronic inflammatory rheumatic disorder affecting spine, peripheral joints and entheses. Patients undergo pain, stiffness and reduced mobility of spine and joints. Patients experience limitations in physical activities and reduced quality of life. Some uncontrolled studies reported benefits of physical activity in patients with AS. The aim of the present study is to assess the efficacy of a physical training program in patients with AS. Patients will be randomized in two parallel arms: program of personalized physical training (intervention group \[PEPc\]) or program of information about physical activity (control group \[PIAP\]). Patients will be evaluated at 12 and 24 weeks on activity, functional and metrological scores (ASAS 20, ASAS 5/6, ASDAS, BASDAI, BASFI, BASMI); biological inflammation (CRP); NSAID use and pain VAS. Primary outcome: percentage of patients reaching an ASAS 20 response at 12 weeks. Secondary outcomes: ASAS 20 at 24 weeks, ASAS5/6, ASDAS, BASDAI, BASFI, BASMI, CRP, NSAID use and pain VAS at 12 and 24 weeks. Statistical analysis: comparison of the percentage of patients reaching an ASAS 20 response at 12 weeks in each arm using a Fisher's exact test (main outcome).
Interventions
9-week personalized physical training program (ergometric bicycle)
Sponsors
Study design
Eligibility
Inclusion criteria
* Patients with AS according to ASAS criteria, * treated or not with NSAID, * synthetic DMARD or anti-TNF agent.
Exclusion criteria
* Contraindications to physical training program (e.g. cardiac failure, pregnancy, painful arthroplasty or lower limbs damaged joint).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of patients reaching an ASAS 20 response | Week 12 |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of patients reaching an ASAS 20 response | Week 24 |
Countries
France